Researcher in Focus: Mr David Galvin
To mark Prostate Cancer Awareness Month, our Researcher in Focus this month is Mr David Galvin, Consultant Urologist at the Mater Misericordiae and St Vincent’s Hospitals and Principal Investigator on the IPCOR (Irish Prostate Cancer Outcomes Research) study, funded by the Irish Cancer Society and Movember.
David graduated from the Royal College of Surgeons in Ireland, Dublin in June 1996. His father, grand-father and brother had all graduated from the same college, and his father worked as an anaesthetist in the Meath hospital for 40 years. He completed his Basic Surgical Training in the Western Surgical Rotation, Galway, followed by two years of laboratory based research for MD Thesis at the Mater Misericordiae Hospital, Dublin and University College Dublin.
David completed his Higher Surgical Training in Urology and was awarded the Urology Fellowship from the Royal College of Surgeons in Ireland in June 2008. He then completed a Fellowship in Urological Oncology at Memorial Sloan Kettering Cancer Centre in New York, finishing in December 2010. He was appointed a Consultant in Urological Oncology in the Essex Cancer Centre before being appointed to both the Mater Misericordiae and St. Vincent’s University hospitals as part of the Dublin Academic Medical Centre. David’s position was funded by the National Cancer Control Program and he is currently Chair of the National Prostate Cancer Leads Network. He is also Head of Research within the Irish Society of Urology, Senior Lecturer in University College Dublin, and Principal Investigator on the Irish Prostate Cancer Outcomes Research study funded by the Irish Cancer Society and Movember to the value of €1.75 million.
For the past nine years the Irish Cancer Society has partnered with the Movember Foundation Ireland in investing in Irish prostate cancer research projects such as IPCOR. The Movember community across Ireland is encouraged to again raise vital life-saving funds that will mean we can continue to invest in prostate cancer research, as well as advocacy and services.
Programmes such as IPCOR rely on funds raised through initiatives such as Movember. To make a donation or see how you can help change the face of men’s health visit ie.movember.com
David lives with his wife Brigid and 3 children in Dublin. His experiences in New York led him to become interested in prostate cancer research. According to David: “My research interests lie in clinical research in to urological cancers, especially outcomes research and epidemiology of prostate cancer and clinical research in to bladder and kidney cancer. My role as the NCCP Chair leads to driving national efforts to improve data collection and to drive improvements in the care of our patients. I am the Principal Investigator of the IPCOR (Irish Prostate Cancer Outcomes Research) project, having received funding from Movember and the Irish Cancer Society to establish a national prostate cancer registry and to conduct research in to it. As Head of Research in the Irish Society of Urology, I have established a Collaborative Research Network (CRN) that will encourage Clinical Urological research throughout all Urology units.”
IPCOR is collecting clinical data and quality of life information from men who have been newly diagnosed with prostate cancer in Ireland and is developing, for the first time, a national prostate cancer registry. IPCOR publishes annual reports on the outcomes of prostate cancer treatment and care. These reports provide evidence-based data to doctors, hospitals and policy makers to inform future healthcare decisions that affect prostate cancer care.
The ultimate goal of IPCOR is to enhance prostate cancer care, improve patient experiences and maximise quality of life for men diagnosed with prostate cancer in Ireland.
The Irish Prostate Cancer Outcomes Research study began in February 2014. The Irish Cancer Society and Movember are supporting this project with funding of €1.75 million over 5 years. This research is being carried out by a collaborative partnership involving the National Cancer Registry Ireland, the HRB Clinical Research Facility in Galway, the National Cancer Control Program and the nation’s major academic institutions represented by Molecular Medicine Ireland.